Zanubrutinib Approved for Relapsed/Refractory Marginal Zone Lymphoma

The FDA has granted accelerated approval to zanubrutinib (Brukinsa®, BeiGene) for the treatment of patients with relapsed/refractory marginal zone lymphoma (MZL) who have received at least one anti–CD20-based regimen. "Marginal zone lymphoma is rare and heterogeneous, and it has been difficult to define optimal therapeutic strategies," wrote Stephen Opat, FRACP, FRCPA, MBBS, Director of Clinical Hematology at Monash Health in Australia, and colleagues, in their publication of the initial results...

Recent Advances in T-Cell Lymphoma: A Conversation with Dr. Steven Horwitz

·

In this podcast, Dr. Steven Horwitz of  Memorial Sloan Kettering Cancer Center discusses recent progress in the treatment and management of T-cell lymphoma. Listen now to hear more!

Improving the Management of Metastatic Breast Cancer: A Conversation With Dr. Sara Tolaney

· Keira Smith: Welcome to Oncology Data AdvisorTM, where we explore the latest advances in cancer research and treatment. I'm Keira Smith. In this podcast, Dr. Sara Tolaney from Dana-Farber Cancer Institute will be discussing strategies for improving the management of patients with metastatic breast cancer. Thank you for joining us, Dr. Tolaney. Sara Tolaney, MD, MPH: Thanks so much for having me. I'm Sara Tolaney. I'm a breast medical oncologist at Dana-Farber Cancer Institute here in Bo...

Atezolizumab Indication Withdrawn from Triple-Negative Breast Cancer Treatment

In consultation with the FDA, the accelerated approval of atezolizumab (Tecentriq®, Genentech) in combination with nab-paclitaxel has been voluntarily withdrawn from the treatment of patients with programmed death ligand 1 (PD-L1)–positive unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). "Triple-negative breast cancer is a heterogenous disease entity with a high unmet medical need," wrote David Miles, MD, Lead Clinician for Breast Cancer at Mount Vernon Cancer Ce...

Optimizing Treatment Planning for Immune Thrombocytopenia: A Video Interview With Allison Imahiyerobo, APN

Keira Smith: Hi. I'm Keira Smith from Oncology Data Advisor. I'm here today with Allison Imahiyerobo. Allison Imahiyerobo: Hi Keira, my name is Alli Imahiyerobo. I'm a nurse practitioner, and I practice at Hematology Oncology Physicians of Englewood in New Jersey. I focus on both benign and malignant hematology. Keira Smith: What are some of the most challenging aspects of treating patients with immune thrombocytopenia, or ITP? Allison Imahiyerobo: I think that it's really twofold. The first cha...

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.